prednisone has been researched along with Constipation in 15 studies
Prednisone: A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver.
prednisone : A synthetic glucocorticoid drug that is particularly effective as an immunosuppressant, and affects virtually all of the immune system. Prednisone is a prodrug that is converted by the liver into prednisolone (a beta-hydroxy group instead of the oxo group at position 11), which is the active drug and also a steroid.
Constipation: Infrequent or difficult evacuation of FECES. These symptoms are associated with a variety of causes, including low DIETARY FIBER intake, emotional or nervous disturbances, systemic and structural disorders, drug-induced aggravation, and infections.
| Excerpt | Relevance | Reference |
|---|---|---|
| "A multicenter phase III study for untreated multiple myeloma was conducted to investigate a switch-induction chemotherapy with melphalan-prednisolone and vincristine-doxorubicin-dexamethasone followed by randomization on maintenance therapy for patients achieving plateau." | 9.15 | Melphalan-prednisolone and vincristine-doxorubicin-dexamethasone chemotherapy followed by prednisolone/interferon maintenance therapy for multiple myeloma: Japan Clinical Oncology Group Study, JCOG0112. ( Ando, K; Asakawa, T; Chou, T; Fukuda, H; Hotta, T; Iida, S; Mizoroki, F; Saito, I; Tobinai, K; Tsukasaki, K; Ueda, R; Uike, N, 2011) |
| "Thalidomide has been reported to be an effective agent for treatment of chronic graft-versus-host disease (CGVHD)." | 9.08 | Thalidomide as salvage therapy for chronic graft-versus-host disease. ( Blume, KG; Chao, N; Forman, SJ; Kashyap, A; Long, GD; Margolin, K; Molina, A; Nademanee, A; Negrin, RS; Niland, JC; O'Donnell, MR; Parker, PM; Planas, I; Schmidt, GM; Smith, EP; Snyder, DS; Somlo, G; Spielberger, R; Stein, AS; Stepan, DE; Wilsman, K; Zwingenberger, K, 1995) |
| "Lubiprostone was more effective than stimulant laxatives at treating vinca alkaloid-induced intractable constipation in patients with hematological malignancies, and its use could enable safe vinca alkaloid chemotherapy." | 5.56 | Effect of lubiprostone on vinca alkaloid-induced constipation in patients with hematological malignancies: a propensity score-matched analysis. ( Fukuda, H; Hayashi, T; Imai, T; Kawada, K; Miyamura, M; Morita, Y; Ohta, T; Tanaka, K, 2020) |
| "Abiraterone is an inhibitor of androgen biosynthesis indicated for the treatment of metastatic castration-resistant prostate cancer." | 5.46 | Abiraterone-induced rhabdomyolysis: A case report. ( Moore, A; Moore, DC, 2017) |
| "A multicenter phase III study for untreated multiple myeloma was conducted to investigate a switch-induction chemotherapy with melphalan-prednisolone and vincristine-doxorubicin-dexamethasone followed by randomization on maintenance therapy for patients achieving plateau." | 5.15 | Melphalan-prednisolone and vincristine-doxorubicin-dexamethasone chemotherapy followed by prednisolone/interferon maintenance therapy for multiple myeloma: Japan Clinical Oncology Group Study, JCOG0112. ( Ando, K; Asakawa, T; Chou, T; Fukuda, H; Hotta, T; Iida, S; Mizoroki, F; Saito, I; Tobinai, K; Tsukasaki, K; Ueda, R; Uike, N, 2011) |
| "Thalidomide has been reported to be an effective agent for treatment of chronic graft-versus-host disease (CGVHD)." | 5.08 | Thalidomide as salvage therapy for chronic graft-versus-host disease. ( Blume, KG; Chao, N; Forman, SJ; Kashyap, A; Long, GD; Margolin, K; Molina, A; Nademanee, A; Negrin, RS; Niland, JC; O'Donnell, MR; Parker, PM; Planas, I; Schmidt, GM; Smith, EP; Snyder, DS; Somlo, G; Spielberger, R; Stein, AS; Stepan, DE; Wilsman, K; Zwingenberger, K, 1995) |
| "Lubiprostone was more effective than stimulant laxatives at treating vinca alkaloid-induced intractable constipation in patients with hematological malignancies, and its use could enable safe vinca alkaloid chemotherapy." | 1.56 | Effect of lubiprostone on vinca alkaloid-induced constipation in patients with hematological malignancies: a propensity score-matched analysis. ( Fukuda, H; Hayashi, T; Imai, T; Kawada, K; Miyamura, M; Morita, Y; Ohta, T; Tanaka, K, 2020) |
| "Abiraterone is an inhibitor of androgen biosynthesis indicated for the treatment of metastatic castration-resistant prostate cancer." | 1.46 | Abiraterone-induced rhabdomyolysis: A case report. ( Moore, A; Moore, DC, 2017) |
| "Patients with orthostatic intolerance, anhidrosis, constipation, urinary dysfunction, sicca syndrome and pupillary dysfunction had higher antibody titers than subjects that did not (P<0." | 1.35 | Antibody titers predict clinical features of autoimmune autonomic ganglionopathy. ( Freeman, R; Gibbons, CH, 2009) |
| "Abdominal pain was the most frequent symptom (100%), and hypoalbuminemia was the most frequent sign (70%)." | 1.32 | Gastrointestinal involvement in chronic granulomatous disease. ( Anaya-O'Brien, S; Anderson, VL; Darnell, DN; Gallin, JI; Hilligoss, DM; Holland, SM; Kleiner, DE; Malech, HL; Marciano, BE; Rosenzweig, SD, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (6.67) | 18.7374 |
| 1990's | 1 (6.67) | 18.2507 |
| 2000's | 5 (33.33) | 29.6817 |
| 2010's | 6 (40.00) | 24.3611 |
| 2020's | 2 (13.33) | 2.80 |
| Authors | Studies |
|---|---|
| Rausch, CR | 1 |
| Jabbour, EJ | 1 |
| Kantarjian, HM | 1 |
| Kadia, TM | 1 |
| Kawada, K | 1 |
| Ohta, T | 1 |
| Fukuda, H | 2 |
| Hayashi, T | 1 |
| Tanaka, K | 1 |
| Imai, T | 1 |
| Morita, Y | 1 |
| Miyamura, M | 1 |
| Hayashi, H | 1 |
| Suzuki, A | 1 |
| Ohata, K | 1 |
| Ishihara, M | 1 |
| Kubota, Y | 1 |
| Kobayashi, R | 1 |
| Shibata, Y | 1 |
| Nakamura, H | 1 |
| Nakamura, N | 1 |
| Kitagawa, J | 1 |
| Tsurumi, H | 1 |
| Shimizu, M | 1 |
| Itoh, Y | 1 |
| Rajendra, A | 1 |
| Devasia, AJ | 1 |
| Francis, NR | 1 |
| Turaka, VP | 1 |
| Marasco, G | 1 |
| Zagari, RM | 1 |
| Bazzoli, F | 1 |
| Moore, DC | 1 |
| Moore, A | 1 |
| Gibbons, CH | 1 |
| Freeman, R | 1 |
| Sternberg, CN | 1 |
| Petrylak, DP | 1 |
| Sartor, O | 1 |
| Witjes, JA | 1 |
| Demkow, T | 1 |
| Ferrero, JM | 1 |
| Eymard, JC | 1 |
| Falcon, S | 1 |
| Calabrò, F | 1 |
| James, N | 1 |
| Bodrogi, I | 1 |
| Harper, P | 1 |
| Wirth, M | 1 |
| Berry, W | 1 |
| Petrone, ME | 1 |
| McKearn, TJ | 1 |
| Noursalehi, M | 1 |
| George, M | 1 |
| Rozencweig, M | 1 |
| Chou, T | 1 |
| Tobinai, K | 1 |
| Uike, N | 1 |
| Asakawa, T | 1 |
| Saito, I | 1 |
| Mizoroki, F | 1 |
| Ando, K | 1 |
| Iida, S | 1 |
| Ueda, R | 1 |
| Tsukasaki, K | 1 |
| Hotta, T | 1 |
| Manabe, M | 1 |
| Hayashi, Y | 1 |
| Yoshii, Y | 1 |
| Mukai, S | 1 |
| Sakamoto, E | 1 |
| Kanashima, H | 1 |
| Nakao, T | 1 |
| Hayama, T | 1 |
| Fukushima, H | 1 |
| Inoue, T | 1 |
| Yamane, T | 1 |
| Teshima, H | 1 |
| Marciano, BE | 1 |
| Rosenzweig, SD | 1 |
| Kleiner, DE | 1 |
| Anderson, VL | 1 |
| Darnell, DN | 1 |
| Anaya-O'Brien, S | 1 |
| Hilligoss, DM | 1 |
| Malech, HL | 1 |
| Gallin, JI | 1 |
| Holland, SM | 1 |
| Herrero Hernández, A | 1 |
| Escobosa Sánchez, O | 1 |
| Acha García, T | 1 |
| Sharma, A | 1 |
| Wanchu, A | 1 |
| Kalra, N | 1 |
| Singh, S | 1 |
| Bambery, P | 1 |
| Parker, PM | 1 |
| Chao, N | 1 |
| Nademanee, A | 1 |
| O'Donnell, MR | 1 |
| Schmidt, GM | 1 |
| Snyder, DS | 1 |
| Stein, AS | 1 |
| Smith, EP | 1 |
| Molina, A | 1 |
| Stepan, DE | 1 |
| Kashyap, A | 1 |
| Planas, I | 1 |
| Spielberger, R | 1 |
| Somlo, G | 1 |
| Margolin, K | 1 |
| Zwingenberger, K | 1 |
| Wilsman, K | 1 |
| Negrin, RS | 1 |
| Long, GD | 1 |
| Niland, JC | 1 |
| Blume, KG | 1 |
| Forman, SJ | 1 |
| Garewal, HS | 1 |
| Dalton, WS | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Double-blind, Randomized, Placebo-controlled Trial to Evaluate the Efficacy of Intravenous Immunoglobulin Therapy in Autoimmune Autonomic Ganglionopathy.[NCT01522235] | Phase 2/Phase 3 | 6 participants (Actual) | Interventional | 2012-02-29 | Completed | ||
| Natural History of Intestinal Inflammation in Patients With Primary Immune Dysregulations[NCT03278912] | 0 participants (Actual) | Observational | 2023-09-08 | Withdrawn (stopped due to Funding completed.) | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The primary outcome, the change in systolic blood pressure during 60 degree tilt (ΔSBP), will be assessed in all study participants at baseline and at 6 weeks. (NCT01522235)
Timeframe: Baseline and 6 weeks
| Intervention | mmHg (Mean) |
|---|---|
| IVIg Group | 42.5 |
| Placebo Group | -12.3 |
To compare the change in systolic blood pressure during 60 degree head up tilt table test after 6 and 12 weeks of IVIG (the within-patient difference in ΔSBP at 12 and 6 weeks among treated patients). (NCT01522235)
Timeframe: 6 weeks and 12 weeks
| Intervention | mmHg (Mean) |
|---|---|
| IVIG Group | -26 |
| Placebo Group | -7.6 |
"To determine the change in autonomic symptoms (measured by the composite autonomic severity score [CASS]) measured at baseline and 6 weeks in individuals receiving IVIg.~Is a 10-point composite autonomic scoring scale of autonomic function. This scale allots 4 points for adrenergic and 3 points each for sudomotor and cardiovagal failure. Subjects with a score of 3 or less on have a mild autonomic failure, 4-6 have moderate autonomic failure and those with scores of 7 to 10 have severe failure. The minimum score possible is 3 and maximum is 10." (NCT01522235)
Timeframe: Baseline, 6 weeks
| Intervention | units (Mean) |
|---|---|
| IVIg Group | 0.5 |
| Placebo Group | 0 |
To determine the change in autonomic symptoms (measured by the composite autonomic symptom score [COMPASS] questionnaire) measured at baseline and 6 weeks. Minimum and maximum score possible: 0-100. We have reported the Total score. Higher values represent worse outcome. (NCT01522235)
Timeframe: Baseline, 6 weeks
| Intervention | units (Mean) |
|---|---|
| IVIg Group | -5 |
| Placebo Group | -0.33 |
"To determine the change in quality of life (measured by the EuroQol [EQ-5D]) measured at baseline and 6 weeks in individuals receiving IVIg. We have reported the subscale (EQ-VAS). The minimum score is 0 and maximum score is 100. (0) corresponds to the worst health you can imagine, and the highest rate (100) corresponds to the best health you can imagine." (NCT01522235)
Timeframe: Baseline, 6 weeks
| Intervention | units (Mean) |
|---|---|
| IVIg Group | 15 |
| Placebo Group | 9.3 |
"To determine the change in orthostatic Hypotension symptom (measured by the orthostatic hypotension symptom assessment questionnaire) measured at baseline and 6 weeks in individuals receiving IVIG. This is a 60 point orthostatic hypotenstion symptom assessment questionnaire. The minimum score possible is 0 and maximum is 60.~Higher values represent worse outcome. We are reporting the total score." (NCT01522235)
Timeframe: Baseline, 6 weeks
| Intervention | units (Mean) |
|---|---|
| Group A | -9 |
| Group B | 12 |
3 trials available for prednisone and Constipation
| Article | Year |
|---|---|
Multinational, double-blind, phase III study of prednisone and either satraplatin or placebo in patients with castrate-refractory prostate cancer progressing after prior chemotherapy: the SPARC trial.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy P | 2009 |
Melphalan-prednisolone and vincristine-doxorubicin-dexamethasone chemotherapy followed by prednisolone/interferon maintenance therapy for multiple myeloma: Japan Clinical Oncology Group Study, JCOG0112.
Topics: Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Constipation; Dexamethasone; Doxorub | 2011 |
Thalidomide as salvage therapy for chronic graft-versus-host disease.
Topics: Adolescent; Adult; Bone Marrow Transplantation; Child; Chronic Disease; Constipation; Cyclosporine; | 1995 |
12 other studies available for prednisone and Constipation
| Article | Year |
|---|---|
Optimizing the use of the hyperCVAD regimen: Clinical vignettes and practical management.
Topics: Age Factors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Brai | 2020 |
Effect of lubiprostone on vinca alkaloid-induced constipation in patients with hematological malignancies: a propensity score-matched analysis.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Pro | 2020 |
Control of Constipation in Patients Receiving CHOP or CHOP-Like Chemotherapy Regimens for Non-Hodgkin's Lymphoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antacids; Antineoplastic Combined Chemotherapy Protocols | 2017 |
Antenatal chemotherapy in a case of diffuse large B-cell lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Constipation; Cyclophosphamide; Diarrhea; Dox | 2018 |
CT-scan fat halo sign in a patient with abdominal mass and constipation.
Topics: Adipose Tissue; Biopsy; Budesonide; Constipation; Female; Glucocorticoids; Humans; Immunohistochemis | 2019 |
Abiraterone-induced rhabdomyolysis: A case report.
Topics: Analgesics, Opioid; Androstenes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemothera | 2017 |
Antibody titers predict clinical features of autoimmune autonomic ganglionopathy.
Topics: Adult; Autoantibodies; Autoantigens; Autoimmune Diseases of the Nervous System; Constipation; Diseas | 2009 |
Primary diffuse large B-Cell lymphoma of the prostate presenting with urinary retention and dyschezia for which rituximab-combined CHOP therapy was effective-a case presentation.
Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Combin | 2012 |
Gastrointestinal involvement in chronic granulomatous disease.
Topics: Abdominal Pain; Adolescent; Adult; Child; Child, Preschool; Colon; Constipation; Diarrhea; Female; G | 2004 |
Successful treatment with vincristine in PHACES syndrome.
Topics: Abnormalities, Multiple; Age Factors; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytog | 2007 |
Successful treatment of severe gastrointestinal involvement in adult-onset Henoch-Schönlein purpura.
Topics: Abdominal Pain; Administration, Oral; Adult; Biopsy; Capillaries; Complement C3; Constipation; Gastr | 2007 |
Metoclopramide in vincristine-induced ileus.
Topics: Aged; Constipation; Gastrointestinal Motility; Humans; Intestinal Obstruction; Leukemia, Lymphoid; L | 1985 |